CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 184 enrolled
Drug / intervention
MiStent DES +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01294748
NCT01294748Phase 2Completed
CompareCT.gov

Clinical Investigation of a DES (MiStent™ System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in Native Coronary Arteries.

Micell Technologies·interventional·Posted Feb 11, 2011·Updated Feb 8, 2017

In Brief

A Phase 2 clinical trial evaluating MiStent DES and Endeavor DES for Coronary Artery Disease. Completed, enrolled 184 participants across 28 sites in 6 countries.

Detailed Summary

The DESSOLVE II clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in the native coronary arteries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBelgium, France, Netherlands, New Zealand, Sweden, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2011
Enrollment StartFeb 1, 2011
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.4 years ago

Interventions

MiStent DESdevice

The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).

Endeavor DESdevice

The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).